Zum Inhalt springen

Updates on COVID-19

This page contains important information and regular developments about anti-doping work during the SARS-CoV-2 pandemic.

In the following, you can find instructions for doping controls during the pandemic, access information regarding the hygiene measures implemented by NADA Germany, and read up-to-date NADA news and statements. Subject specific contact information can be found in the relevant areas.

Protection during doping tests

Testing

NADA takes infection prevention very seriously and has implemented hygiene standards for the control process in accordance with the recommendations of the Robert Koch Institute and the World Anti-Doping Agency. Among others, these measures include wearing mouth and nose protection, intensive hand hygiene as well as surface disinfection. An overview of the measures can be found in the illustration above. All measures taken serve to protect those involved in the control process, in particular the athletes and the control staff.

In light of the SARS-CoV-2 pandemic, doping controls were significantly reduced or suspended from mid-March to mid-May 2020. In order to support clean athletes during the Corona crisis and to protect them from the general suspicion of unrestricted doping, NADA initiated the Dried-Blood-Spot-Method project.  Testing with the DBS method took place from the end of March to the beginning of August. Further information can be found here:
https://www.nada.de/en/testing/development/

NADA Germany requested an external inspection by TÜV Hessen for the implemented hygiene measures and concept during medication testing of horses. The inspection resulted in a seal of quality “Corona Safe”. Further information can be found at https://www.nada.de/en/testing/medication-controls-of-horses/

For any questions or problems, athletes can contact the employees of the Testing department directly at any time: dks[at]nada.de 

Medicine

A large number of already existing and approved medications are currently being tested for the treatment of infections with the SARS-CoV-2 virus. These include, for example, antiviral medications, immunomodulators and medication for people with lung disease. In addition, research is being carried out on completely new pharmaceutical ingredients that have not been approved as medication yet.

No statement can be made at this point to the extent to which potential future medications for the treatment of COVID-19 are or will be part of the current or future WADA prohibited lists, due to the large number of pharmacologically and chemically different active substances that are currently in question. A binding assessment can only be made when the specific active ingredient that is to be used is known.

Inhalation of or ventilation with oxygen is compatible with the doping regulations of WADA (The World Anti-Doping Code. The 2020 Prohibited List. International Standard. 1.1.2020 / The 2021 Prohibited List. International Standard. 1.1.2021).

The antiviral agent remdesivir is compatible with the doping regulations of the WADA (The World Anti-Doping Code. The Prohibited List 2020. International Standard. 1.1.2020 / The Prohibited List 2021. International Standard. 1.1.2021).

The oral, intravenous, intramuscular and rectal use of glucocorticoids is prohibited in competition (The World Anti-Doping Code. The 2020 Prohibited List. International Standard. 1.1.2020 / The 2021 Prohibited List. International Standard. 1.1.2021); this is referred to as systemic administration. This means that the detection of the active ingredient in an in-competition-test is prohibited. The systemic use of glucocorticoids outside of competitions is not prohibited.

Information on applying for a therapeutic use exemption (TUE) for the use of prohibited substances can be found at: https://www.nada.de/en/medicine/when-athletes-fall-ill/therapeutic-use-exemptions-tue/

* Source: https://www.rki.de/DE/Content/Kommissions/Stakob/Stellunghaben/Stellungnahme-Covid-19_Therapie_Diagnose.pdf?__blob=publicationFile

Intravenous infusions and / or injections of more than 100 ml in total within a period of 12 hours, even if the administered substance (s) is / are allowed, may only be carried out upon a granted therapeutic use exemption (TUE) according to the doping regulations of the WADA (The World Anti-Doping Code. The 2020 Prohibited List. International Standard. 1.1.2020 / The 2021 Prohibited List. International Standard. 1.1.2021), unless it is lawful in the course of hospital treatment, surgical intervention or clinical diagnostic examination. You can find information on applying for a Medical Exemption (TUE) for the use of prohibited substances at https://www.nada.de/en/medicine/when-athletes-fall-ill/therapeutic-use-exemptions-tue/

Upon the appeal of clinics and blood donation centers to register as a donor after a recovered virus infection with SARS-CoV-2, we point out to remain considerate of the anti-doping regulations on blood and blood plasma donations. All information can be found at: www.nada.de/medizin/aktuelle-medizinische-hinweise 

As usual, the doping relevance of medication or active ingredients can be queried via our medicine database NADAmed. If you have any further inquiries about medication, the medicine department is available by telephone on 0228/812 92 132 during office hours and by e-mail (medizin[at]nada.de).

Prevention

Inquiries for events (workshops and the information booth) can still be directed to praevention[at]nada.de at any time. Together with the organizers, the possibility of implementation will be reviewed, taking into account general hygiene precautions. However, in accordance with the current official requirements, a planned event can also be canceled at short notice.

Various online offers on prevention content remain available. In addition to the "TOGETHER AGAINST DOPING" e-learning, there is also the online-seminar option. However, these are not a complete substitute for a face-to-face event. Interested parties can contact praevention[at]nada.de.

Media

Requests can be directed at any time to kommunikation[at]nada.de.

Pilotprojekt der NADA 2020: "Dried Blood Spot"-Test